You are viewing the site in preview mode

Skip to main content


  • Poster presentation
  • Open Access

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice

  • 1,
  • 2,
  • 2,
  • 2,
  • 2 and
  • 2
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P360

  • Published:


  • Mammary Carcinoma
  • Prostate Adenocarcinoma
  • Tumor Destruction
  • Carcinoma Model
  • Cell Anergy

Immunotherapy is gathering momentum as a primary therapy for cancer patients. However, monotherapies have limited efficacy in improving outcomes and only benefit a subset of patients. Combination therapies targeting multiple pathways can augment an immune response to further improve survival. Here, we demonstrate that dual anti-OX40/anti-CTLA-4 immunotherapy generated a potent antigen-specific CD8 T cell response, enhancing expansion, effector function, and memory T cell persistence. Importantly, OX40 and CTLA-4 expression on CD8 T cells was critical to maximally promote their expansion following combination therapy. Animals treated with combination therapy and vaccination using anti-DEC-205-HER2 had significantly improved survival in a mammary carcinoma model. Vaccination with combination therapy uniquely restricted Th2-cytokine production by CD4 cells, relative to combination therapy alone, and enhanced IFNα production by CD8 and CD4 cells. We observed an increase in MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, and GM-CSF production by CD8 and CD4 T cells following treatment. Furthermore, this therapy was associated with extensive tumor destruction and T cell infiltration into the tumor. Notably, vaccination with combination therapy reversed anergy and enhanced the expansion and function of CD8 T cells recognizing a tumor-associated antigen in a spontaneous model of prostate adenocarcinoma. Collectively, these data demonstrate that the addition of an anti-DEC-205-HER2 vaccine with combined anti-OX40/anti-CTLA-4 immunotherapy augmented anti-tumor CD8 T cell function, while limiting Th2 polarization in CD4 cells and improving overall survival.

Authors’ Affiliations

Earle A. Chiles Research Institute/Providence Health and Services, Portland, OR, USA
Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA


© Linch et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.